Drug Type Autologous CAR-T |
Synonyms Anti-CD19 anti-CD22 bispecific CAR-T cell therapy (Hrain Biotechnology), Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy(Hrain Biotechnology), Anti-human CD19-CD22 T cell therapy(Hrain Biotechnology Co. Ltd.) + [3] |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators), Immunologic cytotoxicity |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central nervous system leukaemia | Phase 1 | China | 12 Aug 2022 | |
Primary Central Nervous System Lymphoma | Phase 1 | China | 12 Aug 2022 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | China | 10 Feb 2022 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | China | 21 Jan 2022 | |
Refractory B Acute Lymphoblastic Leukemia | Phase 1 | China | 21 Jan 2022 | |
CD19 positive Acute Lymphoblastic Leukemia | Phase 1 | China | 03 May 2018 |